



## **New York State Medicaid Drug Utilization Review (DUR) Board Meeting Agenda – July 23, 2020**

The DUR Board will meet on July 23, 2020, from 9:00 a.m. to 4:30 p.m.  
In consideration of COVID-19 guidelines, there will be no in-person meeting.

The meeting will be available for public viewing by way of a live audio-video webcast. The link to the webcast is available from the Department of Health Events/Webcasts webpage.

<https://www.health.ny.gov/events/webcasts/>

Please monitor this boxed area for any scheduling or webcast changes.

[https://www.health.ny.gov/health\\_care/medicaid/program/dur/index.htm](https://www.health.ny.gov/health_care/medicaid/program/dur/index.htm)

### **Agenda Items**

#### **A. Preferred Drug Program (PDP) Review**

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP (NYS Public Health Law, Section 272 and 273).

- The DUR Board will review clinical and financial information, to recommend preferred and non-preferred drugs.
- For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.
- New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of PDP reviews and submission is discouraged.
- The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at [https://newyork.fhsc.com/downloads/providers/NYRx\\_PDP\\_PDL.pdf](https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf)

- 1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)**  
(Previous review date: 04/27/2016)
- 2. Hepatitis C Agents – Direct Acting Antivirals\***  
(Previous review date: 10/19/2017)  
\* Includes a review of drug utilization and clinical criteria.
- 3. Central Nervous System (CNS) Stimulants**  
(Previous review date: 05/16/2019)
- 4. Acne Agents, Topical**  
(Previous review date: 04/27/2016)
- 5. Topical Steroids, High Potency**  
(Previous review date: 04/26/2018)
- 6. Glucagon-like Peptide-1 Agonists**  
(Previous review date: 04/26/2018)
- 7. Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors**  
(Previous review date: 04/26/2018)
- 8. Sulfasalazine Derivatives**  
(Previous review date: 04/24/2014)
- 9. Immunosuppressives, Oral**  
(Previous review date: 05/16/2019)
- 10. Phosphate Binders/Regulators**  
(Previous review date: 04/27/2017)

## **B. Drug Cap Review**

The DUR Board will review clinical and financial information for the following product which has been identified as contributing to pharmacy expenditures exceeding the Medicaid Drug Cap (NYS Public Health Law, Section 280) and if applicable, recommend a supplemental rebate target amount:

1. Spinraza (nusinersen)

The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at [https://newyork.fhsc.com/downloads/providers/NYRx\\_PDP\\_PDL.pdf](https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf)

**Agenda Timeline** (subject to change based on meeting proceedings)

9:00 – 9:15	Welcome and Opening Comments
9:15 – 10:45	Public Comment Period
10:45 – 12:00	PDP Reviews
12:00 – 1:30	Executive Session/Lunch (PDP Financial Reviews)
1:30 – 2:00	PDP Recommendations
2:00 – 3:30	Drug Cap Review
3:30 – 4:00	Executive Session (Drug Cap Financial Review)
4:00 – 4:15	Drug Cap Recommendation
4:15 – 4:30	Final Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by July 15, 2020. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing [dur@health.ny.gov](mailto:dur@health.ny.gov) (please reference DUR Board Meeting speaker request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment in order to meet meeting timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by July 15, 2020. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by July 8, 2020 or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.

The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at [https://newyork.fhsc.com/downloads/providers/NYRx\\_PDP\\_PDL.pdf](https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf)